Fig. 4: Impact of intensive praziquantel treatment on levels of markers of gut microbial translocation and gut inflammation. | npj Vaccines

Fig. 4: Impact of intensive praziquantel treatment on levels of markers of gut microbial translocation and gut inflammation.

From: Helminth driven gut inflammation and microbial translocation associate with altered vaccine responses in rural Uganda

Fig. 4

Forest plots show geometric mean ratios (GMRs) and 95% confidence intervals (CIs) for associations between praziquantel treatment and levels of markers of gut microbial translocation and gut inflammation, among (a) participants who were S. mansoni infected (CAA ≥ 30 pg/ml) at enrolment (week -6) in both standard and intensive intervention arms, but were S. mansoni negative (CAA < 30 pg/ml) in the intensive arm six weeks later (week 0), and (b) all randomised participants regardless of S. mansoni infection status at enrolment. The reference category for the linear regression model was the standard intervention arm. Sm Schistosoma mansoni, CAA circulating anodic antigen, I-FABP2 intestinal fatty acid-binding protein, LBP lipopolysaccharide (LPS)-binding protein, sCD14 soluble CD14, EndoCab anti-endotoxin core antibodies, fCAL faecal calprotectin, FOB faecal occult blood, fLcn-2 faecal lipocalin-2.

Back to article page